Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 54135419MDD4002 | Other Identifier | Janssen-Cilag S.p.A., Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to describe the pharmacological and non-pharmacological treatment utilization pathways in Italian routine clinical practice of participants with Major Depressive Disorder (MDD) and active suicidal ideation with intent.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with MDD and Active Suicidal Ideation with Intent | Participants with Major Depressive Disorder (MDD) and active suicidal ideation with intent as defined/confirmed by Investigator will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical records of each participant. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No Intervention | Other | No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review. |
| Measure | Description | Time Frame |
|---|---|---|
| Type of Comprehensive Treatment for Major Depression Disorder (MDD) and Active Suicidal Ideation with Intent | Type of comprehensive treatment for MDD and active suicidal ideation with intent (for example, psychopharmacotherapy; psychosocial treatment; somatic therapy) will be reported. | Up to 90 days |
| Number of Psychiatric Drugs | Number of psychiatric drugs (that is, polypsychopharmacy versus monotherapy) will be reported. | Up to 90 days |
| Duration of Treatment | Duration of treatment for MDD and suicidal ideation with intent will be evaluated. | Up to 90 days |
| Sequence of Treatments in Participants with MDD and Suicidal Ideation with Intent | Treatment sequences for participants with MDD and suicidal ideation with intent (for exapmple, administration of first-line antidepressant) will be assessed. | Up to 90 days |
| Care Setting | Care setting (that is, in-patient and out-patient) will be assessed. | Up to 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | The MADRS is a clinician-rated scale designed to measure changes in depression severity due to antidepressant treatment.The MADRS consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms) for a total possible score of 60. Higher scores represent a more severe condition. |
| Measure | Description | Time Frame |
|---|---|---|
| Suicidal ideation and behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score | Suicidal ideation or behavior will be measured using C-SSRS score. C-SSRS is a clinician rated assessment of suicidal behavior and/ or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 yes/no items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Worsening of suicidal ideation will be an increase in severity of suicidal ideation from baseline. |
Inclusion Criteria:
Exclusion criteria:
Not provided
Not provided
Study population consists of participants with confirmed Major Depressive Disorder (MDD) and active suicidal ideation with intent as per physician's opinion.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen-Cilag S.p.A., Italy Clinical Trial | Janssen-Cilag S.p.A. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ASST Spedali Civili Brescia | Brescia | 25123 | Italy | |||
| Ospedale Santissima Trinità |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37837942 | Derived | Pompili M, Dell'Osso BM, Rosso G, Amore M, Bellomo A, Mautone A, Pilotto E, Ramacciotti S, Scardigli MI, Ascione G, Cipelli R, Sansone C, Simoni L, Adami M, Delmonte D; ARIANNA Study Group. Routine treatment pathways in a cohort of patients with major depression and suicidality in Italy: the ARIANNA observational study. Compr Psychiatry. 2023 Nov;127:152430. doi: 10.1016/j.comppsych.2023.152430. Epub 2023 Oct 13. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to Day 104 (End of Visit) |
| European Quality of Life (EuroQol) 5-Dimension 5-Level Questionnaire (EQ-5D-5L) scores | The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). | Up to Day 104 (End of Visit) |
| Percentage of participants with AEs and SAEs | An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A Serious (AE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | Up to Day 104 (End of visit) |
| Healthcare Resource Utilization | Health Care Resource Utilization (HCRU) will be measured through the number of hospitalization visits, visits to the emergency department, inpatient hospitalization, specialist outpatient visits, number of day care visits, laboratory tests, instrumental and other diagnostic tests related to MDD with active suicidal ideation with intent. | Up to day 104 (End of Visit) |
| Up to Day 104 (End of study) |
| Beck Hopelessness Scale (BHS) Score | BHS is paper-based self-reported measure to assess one's level of negative expectations or pessimism regarding future. The scale consists of 20 true-false items that examine the respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9-items are keyed false and 11 are keyed true. Items fall within 3 domains: feelings about future; loss of motivation; future expectations. Each response is assigned a score of 0 or 1. Total BHS score is sum of item responses, with range from 0 to 20, with a higher score representing higher level of hopelessness. Total scores that range from 0 to 3 are (normal range), scores 4 to 8 (mild hopelessness, scores 9 to 14 (moderate hopelessness), scores <14 (severe hopelessness). Negative change in score indicates improvement. | Up to Day 104 (End of visit) |
| Montgomery-Asberg Depression Rating Scale Suicide Ideation: item 10 (MADRS-SI) | MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. MADRS item 10, or MADRS-SI evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts; scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. | Up to Day 104 (End of Visit) |
| Involvement Evaluation Questionnaire (IEQ) | The 31-item Involvement Evaluation Questionnaire measures caregiver burden. It has been validated for caregivers of individuals with schizophrenia, covers a broad domain of caregiving consequences and refers to burden experienced within the past 4 weeks. Mean scores are calculated for the total scale and sub-scales. Total scores can range from 29 to 145 with sub-scale domains ranging - tension, 9-45; supervision, 6-30; worrying, 6-30; and urging, 8-40. Lower total and subscale scores indicate less burden and higher scores greater level of caregiver burden. | Up to Day 104 (End of Visit) |
| Cagliari |
| 00000 |
| Italy |
| Ospedale Sant'Antonio Abate | Cantù | 22063 | Italy |
| Ospedale Vittorio Emanuele | Catania | 95124 | Italy |
| Ospedale Parodi Delfino | Colleferro | 00034 | Italy |
| Ospedali Riuniti Foggia | Foggia | 71122 | Italy |
| Ospedale San Giovanni di Dio | Frattamaggiore | 80027 | Italy |
| Azienda Ospedaliera Universitaria San Martino di Genova | Genova | 16132 | Italy |
| Az. USL 12 di Viareggio Ospedale Versilia | Lido di Camaiore | 53041 | Italy |
| ASST Fatebenefratelli Sacco | Milan | 20157 | Italy |
| Ospedale Ca Granda - Niguarda | Milan | 20162 | Italy |
| Dipartimento di Salute Mentale | Modena | 41126 | Italy |
| Ospedale S Francesco d Assisi | Oliveto Citra | 84020 | Italy |
| Aou San Luigi Gonzaga | Orbassano | 10043 | Italy |
| Centro Salute Mentale | Padova | 35124 | Italy |
| AOU Policlinico P.Giaccone | Palermo | 90127 | Italy |
| H.U. Santa Lucía | Province of Macerata | 62100 | Italy |
| P.O. Putignano | Putignano | 70017 | Italy |
| Ospedale Infermi Rimini | Rimini | 47923 | Italy |
| Azienda Ospedaliera Sant Andrea | Roma | 00196 | Italy |
| Ospedale G. Mazzini | Teramo | 64100 | Italy |
| A.O.U. Città della Salute e della Scienza | Torino | 10126 | Italy |
| Azienda Sanitaria Universitaria Integrata di Udine | Udine | 33100 | Italy |
| Azienda Ulss 8 Berica- Ospedale Di Vicenza | Vicenza | 36100 | Italy |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D059020 | Suicidal Ideation |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D013405 | Suicide |
| D016728 | Self-Injurious Behavior |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided